| URL | http://www.philly.com/philly/blogs/inq-phillydeals |
| Source | Philly.com |
| Date Published | 06/06/2016 |
| Author Name | Joseph N. DiStefano |
| Mentions specific company case(s) of reshoring, kept from offshoring, or transplant | Yes |
| Company/Division name | Frontida BioPharm |
| Parent company | Hangzhou Tigermed Consulting |
| Type of work | Manufacturing |
| If manufacturing, is the company a contract manufacturer? | Yes |
| Reshoring category: | Transplant |
| Year reshoring announced: | 2016 |
| Domestically, the work will be done: | In-house |
| Capital investment ($): | 50.25 |
| Country(ies) from which reshored: | China |
| City reshored to: | Philadelphia |
| State(s) reshored to: | PA |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | Pharmaceuticals |